With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
A tale of two multi-billion schizophrenia deals, AstraZeneca touts strong sales while deflecting questions about an ...
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience ...
Zacks.com on MSN6d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...
Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials of its experimental schizophrenia drug ... AbbVie drug's competitive threat ...
Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback